The dominant trend across this cluster is the rapid maturation and diversification of T-cell-redirecting immunotherapies—BCMA- and GPRC5D-targeted CAR-T (including dual-target and cilta-cel constructs), bispecific antibodies, trispecific antibodies, and antibody-drug conjugates (belantamab mafodotin)—as they move from relapsed/refractory salvage roles into earlier lines of multiple myeloma therapy. The IMMPACT-MM real-world analysis exemplifies this shift, characterizing durable responses to early-line cilta-cel and identifying patient- and disease-specific factors that predict long-term benefit. In parallel, the 2025 Bridging the Gaps Conference formalized this evolution through a modified Delphi consensus process, producing eleven expert recommendations spanning quadruplet induction, individualized maintenance, and sequencing strategies—signaling an industry-wide effort to standardize how clinicians integrate these increasingly complex modalities across the disease continuum from smoldering to heavily relapsed disease. A parallel but structurally analogous trend appears in chronic lymphocytic leukemia and mantle cell lymphoma, where BTK inhibitors, BCL-2 inhibitors, chemoimmunotherapy, and now bispecific antibodies are being layered and sequenced, with resistance increasingly explained by convergent molecular escape mechanisms (BTK, PLCG2, and TP53 mutations) that define "double refractory" disease states requiring novel immune-based salvage.
A second major axis is the systematic characterization of toxicity as therapies proliferate and move earlier in treatment sequences. Toxicity management is now treated as a core clinical competency rather than an afterthought, spanning CAR-T-specific complications and bispecific antibody-associated adverse events. Most notably, cardiotoxicity has emerged as a unifying safety concern across myeloma drug classes, with proteasome inhibitors (carfilzomib singled out as most cardiotoxic) and bispecific antibodies converging on shared mechanistic pathways—mitochondrial dysfunction, unfolded protein response activation, and endothelial/cytokine-mediated injury. Early biomarkers such as GLS worsening and troponin elevation, alongside emerging omics-based risk stratification models, reflect a push toward proactive, mechanism-informed cardiac surveillance rather than reactive management, as synthesized in comprehensive reviews from centers like MD Anderson.
A third thread, seemingly distinct but thematically resonant, is the application of multimodal immunotherapy combination logic to NK/T-cell lymphoma, an EBV-driven, chemoresistant malignancy. Here, antibody-drug conjugates, dual checkpoint inhibitor therapy, EBV-specific cytotoxic T lymphocytes, and radiotherapy combinations are being explored against resistance mechanisms strikingly parallel to those in myeloma and CLL—namely virus-driven immune suppression (EBV-TIME interactions) and multi-checkpoint co-expression enabling immune evasion. Collectively, this cluster reflects a field-wide transition from single-agent cytotoxic paradigms toward rationally sequenced, biomarker-guided, immune-engaging combination regimens, where success is increasingly defined not just by response rates but by durability, resistance mechanism elucidation, and the ability to anticipate and mitigate class-specific toxicities—especially cardiotoxicity—through consensus-driven, individualized treatment algorithms.